IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Here’s What Happened

IPSEN (OTCMKTS:IPSEY) gapped down before the market opened on Friday . The stock had previously closed at $47.11, but opened at $44.81. IPSEN shares last traded at $44.81, with a volume of 170 shares.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IPSEY. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, IPSEN presently has an average rating of “Hold”.

IPSEN Stock Down 4.9%

The company has a 50-day simple moving average of $46.20 and a 200 day simple moving average of $45.15.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).